Summary
This prediction ended on 21.11.13 with a price of €96.10. The BUY prediction by t66wv33c finished with a performance of 15.13%. t66wv33c has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Bayer AG | 4.364% | 4.364% | -46.866% | -46.700% |
iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by t66wv33c for this prediction
In the thread Bayer AG diskutieren
Könnte noch mal weiter steigen!
Laut Handelsblatt hat die EMA für das Augenmittel Eylea von Bayer eine breitere Zulassung in Europa empfohlen. Das Präparat solle künftig auch für die Behandlung eingeschränkter Sehfähigkeit aufgrund von Makula-Ödemen eingesetzt werden können.
Eylea gehört zu den Schlüsselpräparaten der Bayer-Pharmasparte. Bayer traut der Arznei in der Spitze Umsätze oberhalb der Milliardenschwelle zu.